MedTrace Logo

This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.

NCT01458938 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2017-02-01

No results posted yet for this study

Summary

The objective of this pilot study is to determine if degenerative spinal disorders such as acute radiculopathy, myelopathy, stenosis, or disc and facet disease cause detectable alterations in Substance P levels in saliva, serum and cerebrospinal fluid. If this pilot study shows a correlation between Substance P levels and pain associated with degenerative spinal disorders, then a larger study will be initiated to determine the feasibility of using Substance P levels in the diagnosis and treatment of degenerative spinal disease.

Conditions

  • Spinal Disease
  • Spinal Radiculopathy
  • Myelopathy
  • Neurogenic Claudication

Interventions

OTHER

treatment plan

Data Collection Study

Sponsors & Collaborators

  • Carolina Neurosurgery & Spine Associates

    lead OTHER

Principal Investigators

  • Vinay Deshmukh, M.D. · Carolina Neurosurgery & Spine Associates

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458938 on ClinicalTrials.gov